PP
SLRN

PDT Partners’s ACELYRIN SLRN Stock Holding History

PDT Partners’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,860
Closed -$68.6K – 845
2024
Q4 		$68.6K Sell
21,860
-58,684
-73% -$284K 0.01% 696
2024
Q3 		$397K Sell
80,544
-23,309
-22% -$120K 0.04% 554
2024
Q2 		$458K Buy
+103,853
New +$487K 0.04% 486
2024
Q1 		– Sell
-57,896
Closed -$432K – 683
2023
Q4 		$432K Sell
57,896
-36,706
-39% -$313K 0.05% 425
2023
Q3 		$962K Buy
+94,602
New +$2.01M 0.12% 297

Other funds holding SLRN

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

PDT Partners's SLRN Position: Q1 2025 in Review

PDT Partners sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 21,860 shares — an estimated $68.6K sold.

PDT Partners first reported a position in SLRN in Q3 2023 and held it in 5 quarters. The position peaked at $962K in Q3 2023. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • PDT Partners reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • PDT Partners sold 21,860 ACELYRIN shares in Q1 2025, an estimated $68.6K.
  • PDT Partners first reported a position in ACELYRIN in Q3 2023 and held it in 5 quarters.
  • PDT Partners's ACELYRIN position peaked at $962K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on PDT Partners's 13F filing for Q1 2025, filed 15 May 2025.